title: Next generation of weight management medications: implications for diabetes and CVD risk.
abstract: Since the 1980s, the prevalence of obesity has almost doubled worldwide. Treatments for obesity include lifestyle modification, medications and surgery. Newer anti-obesity medications have been shown to be effective at inducing initial weight management in addition to successful long-term weight maintenance. Historically, weight management medications have been associated with public safety concerns that have resulted in the majority being withdrawn from the market or never receiving medicinal authorization. Recently, several countries have approved some newer generation weight management medications which may be beneficial to combat obesity. These medications have varying effects on cardiometabolic parameters, both positive and potentially negative. This review will outline the mechanisms of action of these medications and their implications for both diabetes and cardiovascular risks.
authors.affiliation: Weight Management and Diabetes Management, The Wharton Medical Clinic, 414 Victoria Ave N Suite 14, Hamilton, ON, L8L 5G8, Canada, wharton.sean@gmail.com.
authors.forename: S
authors.initials: S
authors.lastname: Wharton
authors.forename: K J
authors.initials: KJ
authors.lastname: Serodio
mesh_terms: D019440:Anti-Obesity Agents / Q000145:classification* / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D006801:Humans; D009765:Obesity / Q000150:complications* / Q000188:drug therapy*; D012307:Risk Factors; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D019440:Anti-Obesity Agents